Pain News and Research

Latest Pain News and Research

St. Jude Medical fourth quarter net sales increase 4% to $1.407B

St. Jude Medical, Inc. today reported sales and net earnings for the fourth quarter and year ended December 31, 2011.

25 Jan 2012

One-year results from Covidien's EverFlex stent trial on P.A.D.

Covidien, a leading global provider of healthcare products, today announced that one-year results on the use of its EverFlex stent for superficial femoral artery stenting were presented here during the International Symposium on Endovascular Therapy (ISET) Conference.

25 Jan 2012

Enrollment complete in Medtronic's CoreValve U.S. Trial for severe aortic stenosis

Medtronic, Inc. today announced it has completed patient enrollment in the extreme risk study in its CoreValve U.S. Pivotal Trial. The company also received approval from the U.S. Food and Drug Administration (FDA) for an extended investigation to continue enrolling extreme risk patients under a Continued Access Study protocol.

From Medtronic 25 Jan 2012

OraQuick HIV1/2 test as accurate as traditional blood test

A saliva test used to diagnose the human immunodeficiency virus (HIV), is comparable in accuracy to the traditional blood test, according to a new study led by the Research Institute of the McGill University Health Centre (RI-MUHC) and McGill University.

25 Jan 2012

IHS experts develop new guidelines for migraine clinical trials

Experts from the International Headache Society (IHS) have developed new recommendations for conduct of acute and preventive migraine clinical trials. The third edition of Migraine Clinical Trials Guidelines is now available in the IHS journal Cephalalgia, which is published by SAGE.

25 Jan 2012

Genoscience, BioLineRx to develop and commercialize BL-8020 for HCV

BioLineRx, a biopharmaceutical development company, announced today it has signed a worldwide, exclusive license agreement with Genoscience, a French company focused on viral disease therapeutics, to develop and commercialize BL-8020, an orally available treatment for Hepatitis C.

24 Jan 2012

Johnson & Johnson fourth quarter sales increase 3.9% to $16.3 billion

Johnson & Johnson today announced sales of $16.3 billion for the fourth quarter of 2011, an increase of 3.9% as compared to the fourth quarter of 2010. Operational sales increased 4.0% and the negative impact of currency was 0.1%.

24 Jan 2012

Women feel pain more than men: Study

A new study showed that women experience more intense pain than men. The study published in the Jan. 23 issue of the Journal of Pain, further suggests that greater effort is needed to recruit women into studies in order to determine the reasons for this gender difference. The Stanford University School of Medicine investigators examined pain scores from tens of thousands of patients in the United States.

24 Jan 2012

EMR data mining reveals that women report more-intense pain than men

Women report more-intense pain than men in virtually every disease category, according to Stanford University School of Medicine investigators who mined a huge collection of electronic medical records to establish the broad gender difference to a high level of statistical significance.

24 Jan 2012

InSightec seeks FDA premarket approval for ExAblate treatment of pain palliation of bone metastases

InSightec Ltd, the leader in MR guided Focused Ultrasound therapy, announced that it has submitted a premarket approval application (PMA) to the U.S. Food and Drug Administration (FDA) for its ExAblate treatment of pain palliation of bone metastases.

24 Jan 2012

Covidien releases results of TurboHawk and SpiderFX combination study on P.A.D.

Covidien, a leading global provider of healthcare products, today released the results of the DEFINITIVE Ca++ study.

24 Jan 2012

Baxter to commence second GAMMAGARD LIQUID Phase III trial in Alzheimer's

Baxter International Inc. today provided an update on its clinical program evaluating the use of its GAMMAGARD LIQUID 10%, for the treatment of mild to moderate Alzheimer's disease.

From Baxter International Inc. 24 Jan 2012

Takeda receives FDA approval for VELCADE sNDA to treat MM

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE(bortezomib), which updates the label to include the subcutaneous method of administration in all approved indications: multiple myeloma and mantle cell lymphoma after at least one prior therapy.

24 Jan 2012

FDA grants 510(k) clearance for Medtronic's Aquamantys SBS 5.0 Sheathed Bipolar Sealer

Medtronic, Inc. announced today that it has received 510(k) clearance from the Food and Drug Administration (FDA) for the Aquamantys® SBS 5.0 Sheathed Bipolar Sealer, a new addition to the spine portfolio of the company's Advanced Energy business.

From Medtronic 23 Jan 2012

FzioMed's DYNAVISC adhesion barrier gel receives European CE Mark approval

FzioMed, Inc. is pleased to announce that it has received CE Mark approval to market DYNAVISC adhesion barrier gel in Europe for tendon and peripheral nerve surgery.

23 Jan 2012

Welch Allyn's Connex IWS, EVD System and ProBP 3400 to be showcased at Arab Health 2012

Welch Allyn, a leading global provider of medical diagnostic devices headquartered in Skaneateles Falls, NY, will showcase its newest generation of connected solutions designed to address the needs of busy medical practices this week at Arab Health 2012 in Dubai.

23 Jan 2012

Scientists use metabolomics to discover DMS linked with neuropathic pain

Millions of people worldwide suffer from a type of chronic pain called neuropathic pain, which is triggered by nerve damage. Precisely how this pain persists has been a mystery, and current treatments are largely ineffective. But a team led by scientists from The Scripps Research Institute, using a new approach known as metabolomics, has now discovered a major clue: dimethylsphingosine (DMS), a small-molecule byproduct of cellular membranes in the nervous system.

23 Jan 2012

SSRI use raises risk of fall among elderly with dementia: Study

A new study reveals that nursing home residents with dementia who use selective serotonin reuptake inhibitors (SSRIs) have an increased risk of having a fall that causes injury compared with those who do not use SSRIs. Additionally those using average doses have 3 times the risk compared with nonusers, the authors, led by Carolyn S. Sterke, from Erasmus University Medical Center, Rotterdam, the Netherlands, report. Authors write, “Even at low doses, SSRIs are associated with increased risk of an injurious fall in nursing home residents with dementia.”

22 Jan 2012

Study evaluates whether PWB predicts negative affectivity in fibromyalgia

Fibromyalgia (FM) is a stress-related functional somatic syndrome consisting of musculoskeletal pain and tenderness, and additional symptoms such as fatigue and difficulty concentrating. Factors such as ill-being, often assessed as negative affectivity, may follow, increasing the risk of unhealthy and dysfunctional lifestyles.

21 Jan 2012

EMA CHMP issues positive opinion to MSD's REMICADE for treatment of pediatric UC

MSD today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the use of REMICADE (infliximab) in the treatment of severely active ulcerative colitis (UC) in pediatric patients ages 6 to 17 years, who have had an inadequate response to conventional therapy, including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies.

21 Jan 2012